Cover Image
Market Research Report

Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

Published by BCC Research Product code 913367
Published Content info 127 Pages
Delivery time: 1-2 business days
Price
Back to Top
Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry
Published: September 30, 2019 Content info: 127 Pages
Description

Report Highlights:

This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.

Report Scope:

The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The report includes drug overviews, mechanisms of action, disease backgrounds, currently available treatments for diseases that these drugs address, clinical evidence on safety and efficacy, regulatory scenarios, market scope of the drugs and company profiles of manufactures.

Report Includes:

  • Information on the top potential drug launches by pharma companies in 2019
  • Knowledge about drug, mechanism of action, and briefing of clinical evidences
  • Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more
  • Insights into regulatory approvals, market scope, and analysis of pipeline molecules
  • Detailed profiles of the companies and competitors related to the industry
Table of Contents
Product Code: PHM220A

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Significant Drug Launches

Chapter 3: Ultomiris (Ravulizumab)

  • Overview of Ultomiris
  • Scientific Summary
    • Pharmacodynamics and Mechanism of Action
    • Pharmacokinetics
    • Therapeutic Trials of Ultomiris on Safety and Efficacy
    • Adverse Drug Reactions
  • Disease Background
    • Epidemiology of PNH
    • Pathophysiology
    • Symptoms of PNH
  • Currently Available Treatment for PNH
  • Pipeline Molecules for PNH
  • Regulatory and Development Milestones of Ultomiris
  • Market Scope for Ultomiris
    • Current PNH Market
    • Ultomiris Market
    • Market Drivers
    • Pharmaceutical Pricing and Reimbursement
    • Ultomiris Exclusivity
  • Company Profile
    • ALEXION PHARMACEUTICALS INC.

Chapter 4: Rinvoq (Upadacitinib)

  • Drug Overview
  • Scientific Summary
    • Pharmacodynamics and Mechanism of Action
    • Pharmacokinetics
    • Therapeutic Trials of Upadacitinib on Safety and Efficacy
    • Adverse Drug Reactions
  • Disease Background
    • Epidemiology
    • Pathophysiology of RA
    • Etiology
    • Symptoms of RA
    • Unmet Needs
  • Current Available Treatment for RA
  • Pipeline Molecules
  • Regulatory Status of Upadacitinib
  • Market Scope for Upadacitinib
    • Current RA Market
    • Market Drivers
    • Upadacitinib Market
  • Company Profile
    • ABBVIE INC.

Chapter 5: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
  • Disease Background
    • Classification of SMA
    • Epidemiology
    • Pathophysiology
  • SMA Therapeutics Pipeline
  • Currently Available Treatment for SMA
  • Market Scope for Drug XX
    • Current SMA Market
    • Drivers for SMA Market
    • Drug XX Market
  • Company Profile
    • NOVARTIS AG

Chapter 6: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
    • Therapeutic Trials of Brolucizumab on Safety and Efficacy
  • Disease Background
    • Epidemiology
    • Disease Subtypes
    • Classification of AMD
    • Etiology
    • Pathophysiology
    • Unmet Needs of AMD
  • Currently Available Treatment for AMD
    • Laser Photocoagulation
    • Photodynamic Therapy
    • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs
  • Pipeline Molecules for AMD
  • Status of Regulatory Approval of Drug XX
  • Market Scope for Drug XX
    • Current Market Size of AMD
    • Market Drivers
    • Impact of Drug XX on AMD Market
  • Company Profile

Chapter 7: Drug XX

  • Drug Overview
  • Scientific Summary
    • Pharmacokinetics
    • Mechanism of Action
    • Adverse Events
    • Therapeutic Trials on Safety and Efficacy of Mayzent
  • Disease Background
    • Epidemiology
    • Pathophysiology
    • Types of MS
    • Symptoms of MS
    • Unmet Needs of MS
  • Regulatory Approval of Drug XX
  • Current Available Treatment for MS
  • Pipeline Molecules for MS
  • Market Scope for Drug XX
    • Current Multiple Sclerosis Market
    • Impact of Drug XX on MS Market
  • Company Profiles

Chapter 8: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
    • Pharmacokinetics
    • Therapeutic Trials on Efficacy and Safety of Risankizumab
  • Disease Background
    • Epidemiology
    • Pathophysiology
    • Types of Psoriasis
  • Regulatory and Development Milestones
  • Currently Available Treatment for Psoriasis
    • Biologics
    • Systemics
    • Phototherapy
  • Pipeline Molecules
  • Market Scope for Drug XX
    • Current Psoriasis Market
    • Drug XX Market
  • Company Profiles

Chapter 9: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
    • Therapeutic Trials on Safety and Efficacy of LentiGlobin
  • Disease Background
    • Epidemiology
    • Types of Thalassemia
    • Pathophysiology
  • Regulatory and Development Milestones
  • Currently Available Treatment
    • Chelating Therapy
  • Pipeline Molecules
  • Market Scope for Drug XX
    • Current Beta Thalassemia Market
    • Drug XX Market
  • Company Profile
    • BLUEBIRD BIO INC.

Chapter 10: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
    • Therapeutic Trials on Safety and Efficacy of Ozanimod
  • Disease Background
    • Epidemiology
    • Pathophysiology
    • Types of MS
    • Symptoms of MS
    • Unmet Needs of MS
  • Currently Available Treatment for MS
  • Pipeline Molecules of MS
  • Regulatory and Developmental Milestones
  • Market Scope for Drug XX
  • Company Profile
    • CELGENE CORP.

Chapter 11: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
    • Therapeutic Trials on Safety and Efficacy of AR101
  • Disease Background
    • Types of Allergic Reactions
    • Focus on Peanut Allergy
  • Management of Peanut Allergy
  • Regulatory and Development Milestones
  • Market Scope for Drug XX
  • Company Profile
    • AIMMUNE THERAPEUTICS INC.

Chapter 12: Drug XX

  • Drug Overview
  • Scientific Summary
    • Mechanism of Action
    • Therapeutic Trials on Efficacy and Safety of Filgotinib
  • Disease Background
    • Epidemiology
    • Pathophysiology of RA
    • Etiology
    • Symptoms of RA
    • Unmet Needs
  • Currently Available Treatment for Rheumatoid Arthritis
  • Pipeline Molecules
  • Market Scope for Drug XX
    • Current RA Market
    • Drug XX Market
  • Company Profile
    • GILEAD SCIENCES INC.

Chapter 13: Conclusion

Chapter 14: Appendix: Acronyms

List of Tables

  • Table 1: Potential Launches to Watch, 2019
  • Table 2: Top Companies Investing in R&D, 2018
  • Table 3: Potential Drug Launches, 2018
  • Table 4: Key Clinical Trials of Ultomiris
  • Table 5: Common Symptoms of PNH
  • Table 6: Other Pipeline Drugs for PNH
  • Table 7: Key Development Milestones of Ultomiris
  • Table 8: Alexion Pharmaceuticals Inc.: Financial Performance, 2016-2018
  • Table 9: Alexion Pharmaceuticals Inc.: Product Portfolio
  • Table 10: Alexion Pharmaceuticals Inc.: Pipeline Molecules
  • Table 11: Alexion Pharmaceuticals, Inc.: Recent Acquisitions
  • Table 12: Clinical Evidence of Safety and Efficacy of Upadacitinib
  • Table 13: Epidemiological Forecast for Diagnosed Prevalent Cases of Rheumatoid Arthritis, by Region, Through 2022
  • Table 14: Common Symptoms of RA
  • Table 15: Unmet Needs of RA
  • Table 16: Current Treatment for RA
  • Table 17: Pipeline Molecules for RA
  • Table 18: Others Pipeline Drug for JAK Inhibitors
  • Table 19: AbbVie, Inc.: Financial Performance, 2016-2018
  • Table 20: AbbVie Inc.: Product Portfolio
  • Table 21: AbbVie Inc.: Pipeline Molecules
  • Table 22: AbbVie Inc.: Recent Acquisitions
  • Table 23: Classification of SMA
  • Table 24: Milestones in Discovery of SMA
  • Table 25: Pipeline Molecules, SMA
  • Table 26: Novartis AG: Financial Performance, 2016-2018
  • Table 27: Novartis AG: Product Portfolio, Oncology
  • Table 28: Novartis AG: Product Portfolio, Ophthalmology
  • Table 29: Novartis AG: Product Portfolio, Immunology Hepatology and Dermatology
  • Table 30: Novartis AG: Product Portfolio, Neuroscience
  • Table 31: Novartis AG: Product Portfolio, Respiratory
  • Table 32: Novartis AG: Product Portfolio, Pipeline Molecules
  • Table 33: Novartis AG: Recent Acquisitions
  • Table 34: Therapeutic Trials of Brolucizumab on Safety and Efficacy
  • Table 35: Projected Number of People with AMD, by Region, Through 2024
  • Table 36: AREDS Classification of AMD
  • Table 37: Pipeline Molecules for AMD
  • Table 38: Market Size of Lucentis and Eylea, Through 2022
  • Table 39: Incident and Prevalent Cases of MS, by Country, 2016
  • Table 40: Incident and Prevalent Cases of MS, by Region, 2016
  • Table 41: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
  • Table 42: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
  • Table 43: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
  • Table 44: Pipeline Molecules for Multiple Sclerosis Showing Promising Results
  • Table 45: Development Milestones of Risankizumab
  • Table 46: Currently Available Treatment for Psoriasis, Biologics
  • Table 47: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase III
  • Table 48: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase II
  • Table 49: Global Psoriasis Market, by Region/Country, Through 2022
  • Table 50: Pipeline Molecules: Beta Thalassemia
  • Table 51: Bluebird Bio Inc.: Financial Performance, 2016-2018
  • Table 52: Bluebird Bio Inc.: Pipeline Molecules as of 2019
  • Table 53: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
  • Table 54: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
  • Table 55: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
  • Table 56: Pipeline Molecules of Multiple Sclerosis Showing Promising Results
  • Table 57: Development Milestones of Ozanimod as of 2019
  • Table 58: Celgene Corp.: Revenue Details, 2016-2018
  • Table 59: Celgene Corp.: Marketed Products
  • Table 60: Celgene Corp.: Company Agreements
  • Table 61: Common Symptoms of Peanut Allergy
  • Table 62: Common Symptoms of Rheumatoid Arthritis
  • Table 63: Unmet Needs of Rheumatoid Arthritis
  • Table 64: Current Treatment for Rheumatoid Arthritis
  • Table 65: Pipeline Molecules for Rheumatoid Arthritis
  • Table 66: Gilead Sciences Inc.: Net Revenue, 2016-2018
  • Table 67: Gilead Science Inc.: Marketed Products
  • Table 68: Gilead Science Inc.: Pipeline Molecules
  • Table 69: Acronyms Used in This Report

List of Figures

  • Figure 1: Percentage Distribution of R&D Spending for Clinical Development of Novel Drugs, by Therapeutic Category, 2019
  • Figure 2: Market Share Analysis of Major Players in the Global Pharmaceutical Industry, 2018
  • Figure 3: Soliris: Net Product Revenues, 2014-2018
  • Figure 4: Spinraza: Market Size, 2016-2018
  • Figure 5: Novartis AG: Spending on Research and Development, by Division, 2017 and 2018
  • Figure 6: Brolucizumab: Mechanism of Action
  • Figure 7: Top Eight Food Items Triggering Allergy and Number of Children Affected, 2018
  • Figure 8: Percentage Distribution of Drug Launches, by Therapeutic Category, 2019
Back to Top